Evidence map›Paper›PMID 34891165›Full record

Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination.

Li Tang, Sean Cherry, Elaine I Tuomanen, Ericka Kirkpatrick Roubidoux, Chun Yang Lin, Kim J Allison, Ashleigh Gowen, Pamela Freiden, E Kaitlynn Allen, Yin Su and 8 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Li TangDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Sean CherryDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Elaine I TuomanenDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Ericka Kirkpatrick RoubidouxDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Chun Yang LinDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Kim J AllisonDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Ashleigh GowenDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pamela FreidenDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
E Kaitlynn AllenDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Yin SuDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Aditya H GaurDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jeremie H EsteppDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Maureen A McGargillDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-0916-0372
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4121-776X
Paul G ThomasDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Stacey Schultz-CherryDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-2021-727X
Joshua WolfDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-9912-3646
St. Jude Investigative Team
St. Jude Children's Research Hospital · USIcahn School of Medicine at Mount Sinai · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Household Respiratory Virus SARS-CoV-2 Transmission and Immunity Sub-Study (HRTS)U01AI144616 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GORDON, AUBREE L, THOMAS, PAUL G. · 2019 to 2025
$43.7M
DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9M
NCI NIH HHS 75N91019D00024NCI NIH HHS P30 CA021765NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00052NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CNIAID NIH HHS U01 AI144616NIAID NIH HHS U01 AI150747
6 · The paper itself

Abstract

backgroundFollowing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination there is significant variability between individuals in protective antibody levels against SARS-CoV-2, and within individuals against different virus variants. However, host demographic or clinical characteristics that predict variability in cross-reactive antibody levels are not well-described. These data could inform clinicians, researchers, and policymakers on the populations most likely to require vaccine booster shots.

methodsIn an institutional review board-approved prospective observational cohort study of staff at St. Jude Children's Research Hospital, we identified participants with plasma samples collected after SARS-CoV-2 infection, after mRNA vaccination, and after vaccination following infection, and quantitated immunoglobulin G (IgG) levels by enzyme-linked immunosorbent assay to the spike receptor binding domain (RBD) from 5 important SARS-CoV-2 variants (Wuhan Hu-1, B.1.1.7, B.1.351, P.1, and B.1.617.2). We used regression models to identify factors that contributed to cross-reactive IgG against 1 or multiple viral variants.

resultsFollowing infection, a minority of the cohort generated cross-reactive antibodies, IgG antibodies that bound all tested variants. Those who did had increased disease severity, poor metabolic health, and were of a particular ancestry. Vaccination increased the levels of cross-reactive IgG levels in all populations, including immunocompromised, elderly, and persons with poor metabolic health. Younger people with a healthy weight mounted the highest responses.

conclusionsOur findings provide important new information on individual antibody responses to infection/vaccination that could inform clinicians on populations that may require follow-on immunization.

Indexed as

COVID-19SARS-CoV-2AdultAgedAntibodies, NeutralizingAntibodies, ViralHumansImmunoglobulin GMiddle AgedProspective StudiesSpike Glycoprotein, CoronavirusVaccinationAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody responseBMImetabolic healthSARS-CoV-2variants of concern

Identifiers

PMID34891165
PMCPMC8689782
OpenAlexW4200159443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.